Randomized Phase II Study Comparing Two Different Schedules of Palbociclib Plus Second Line Endocrine Therapy in Women With Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Apr 2017
At a glance
- Drugs Palbociclib (Primary) ; Aromatase inhibitors
- Indications Breast cancer
- Focus Therapeutic Use
- 22 Mar 2017 Planned End Date changed from 1 Dec 2018 to 1 Feb 2019.
- 22 Mar 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Feb 2018.
- 10 Feb 2017 Status changed from recruiting to active, no longer recruiting.